ALI BEN-JACOB, MD

LOGAN, UT

Research Active
Internal Medicine - Hematology & Oncology NPI registered 21+ years 3 publications 2007 – 2008 NPI: 1083611669
Internal Medicine - Hematology & Oncology
NeoplasmsAntineoplastic AgentsDouble-Blind MethodSurvival RateAnemiaBlood TransfusionPulmonary EmbolismVenous ThrombosisHemoglobinsDose-Response Relationship, DrugDarbepoetin alfaErythropoietinPlacebosSafetyHematinics

Practice Location

1281 NORTH 600 EAST
LOGAN, UT 84341-2443

Phone: (435) 752-5999

What does ALI BEN-JACOB research?

Dr. Ali Ben-Jacob studies anemia, a condition where patients have low levels of red blood cells, particularly in the context of cancer. His research investigates how well the medication darbepoetin alfa works for individuals who are experiencing anemia, whether due to cancer alone or as a side effect of cancer treatments like chemotherapy. By comparing immediate and delayed treatment strategies, he seeks to provide valuable insights into managing anemia more effectively, helping patients achieve better energy levels and quality of life.

Key findings

  • In a phase II study, 69% of cancer patients treated with darbepoetin alfa showed improvement in blood levels, compared to only 24% on a placebo.
  • For patients experiencing chemotherapy-induced anemia, 14% of those who received immediate treatment with darbepoetin alfa needed blood transfusions, versus 31% in the delayed treatment group.
  • Patients receiving darbepoetin alfa saw their hemoglobin rise by an average of 2.1 grams per deciliter over 12 weeks, with only 8% requiring transfusions, compared to 22% in the non-treated group.

Frequently asked questions

Does Dr. Ben-Jacob study anemia?
Yes, Dr. Ben-Jacob specifically studies anemia in cancer patients, focusing on how to manage and treat this condition effectively.
What treatments has Dr. Ben-Jacob researched?
He has researched the effects of the drug darbepoetin alfa in treating anemia, both in cancer patients not undergoing chemotherapy and those receiving chemotherapy.
Is Dr. Ben-Jacob's work relevant to chemotherapy patients?
Yes, his research directly addresses the needs of chemotherapy patients suffering from anemia, aiming to improve their treatment outcomes and quality of life.

Publications in plain English

Treating anemia of cancer with every-4-week darbepoetin alfa: final efficacy and safety results from a phase II, randomized, double-blind, placebo-controlled study.

2008

The oncologist

Gordon D, Nichols G, Ben-Jacob A, Tomita D, Lillie T +1 more

Plain English
This study looked at how well a drug called darbepoetin alfa works in treating anemia in cancer patients who are not getting chemotherapy or radiation. Out of the patients treated, 69% on darbepoetin alfa showed improvement in their blood levels compared to only 24% on the placebo. Additionally, 85% of those on darbepoetin alfa reached the desired hemoglobin level, compared to 50% on the placebo, showing that the drug is effective in increasing hemoglobin without adding risk of serious side effects. Who this helps: This research benefits cancer patients suffering from anemia, especially those not undergoing chemotherapy or radiation.

PubMed

Efficacy and safety of every-2-week darbepoetin alfa in patients with anemia of cancer: a controlled, randomized, open-label phase II trial.

2007

The oncologist

Charu V, Belani CP, Gill AN, Bhatt M, Tomita D +2 more

Plain English
This study looked at the effects of darbepoetin alfa, a medication, on patients with anemia caused by cancer. Over 12 weeks, patients who received the medication saw their hemoglobin levels rise by an average of 2.1 grams per deciliter and had fewer transfusions (8%) compared to those who did not get the medication (22%). These improvements led to better energy levels and overall quality of life for the patients. Who this helps: This benefits cancer patients suffering from anemia, providing them with better treatment options to manage their symptoms.

PubMed

A randomized, open-label, multicenter trial of immediate versus delayed intervention with darbepoetin alfa for chemotherapy-induced anemia.

2007

The oncologist

Charu V, Saidman B, Ben-Jacob A, Justice GR, Maniam AS +4 more

Plain English
This study looked at how starting treatment with a drug called darbepoetin alfa right away affects patients undergoing chemotherapy who have low red blood cell levels (anemia). The results showed that 29% of patients who began treatment immediately experienced a drop in hemoglobin to dangerously low levels, compared to 65% in the group that waited for treatment until their hemoglobin dropped further. Additionally, fewer patients in the immediate treatment group needed blood transfusions (14%) compared to those who were treated later (31%), and more patients quickly reached the desired hemoglobin level. Who this helps: This research benefits cancer patients experiencing anemia from chemotherapy, helping them manage their symptoms better and potentially leading to a smoother treatment experience.

PubMed

Frequent Co-Authors

Dianne Tomita Veena Charu Greg Rossi David Gordon Gwen Nichols Tom Lillie Carole Miller Bruce Saidman Glen R Justice Ajit S Maniam

Physician data sourced from the NPPES NPI Registry . Publication data from PubMed . Plain-English summaries generated by AI. Not medical advice.